

# Hepatitis C Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/HD19452106C3EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: HD19452106C3EN

## Abstracts

The 7 major hepatitis c markets reached a value of US\$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 47.1 Billion by 2034, exhibiting a growth rate (CAGR) of 9.14% during 2024-2034.

The hepatitis C market has been comprehensively analyzed in IMARC's new report titled "Hepatitis C Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatitis C refers to an infectious disease caused by the hepatitis C virus that mainly affects the liver. It is transmitted through contact with blood from an infected person. The virus can result in both acute and chronic hepatitis, with symptoms ranging from mild to life-threatening, including liver cirrhosis and cancer. Some of the common indications associated with this condition are nausea, vomiting, fatigue, fever, muscle or joint pains, decreased appetite, abdominal pain, weight loss, jaundice, etc. Additionally, a few people may also experience dark urine and pale stools. The diagnosis of the ailment is based on the patient's medical history, a physical exam, and blood tests. The healthcare provider may perform a genetic work-up to monitor the type of hepatitis C virus (genotype). Various other investigations, such as enzyme-linked immunosorbent assay (ELISA), recombinant immunoblot assay, RNA polymerase chain reaction, etc., are utilized to detect antibodies against the virus. In addition to this, liver ultrasound and biopsy are required to examine liver damage and confirm a diagnosis.

The increasing incidences of injection drug use involving needle and syringe sharing, which can enhance the risk of virus transmission, are primarily driving the hepatitis C market. In addition to this, the rising prevalence of long-term kidney dialysis that can cause cross-contamination from surfaces and supplies due to failure to follow infection-

control guidelines within the unit is also bolstering the market growth. Furthermore, the widespread adoption of antiviral drugs, including pegylated interferon and ribavirin, for treating the disease is acting as another significant growth-inducing factor. These medications can inhibit viral DNA synthesis and reduce the virus's ability to replicate. Additionally, several key players are making extensive investments in R&D activities to launch therapeutic vaccine technology to stimulate immunity among the population. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of combination therapy involving immune modulator drugs and nucleoside analogs, owing to its numerous advantages, such as slowing down or stopping viral reproduction and improving patient outcomes, is expected to drive the hepatitis C market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hepatitis C market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatitis C and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis C market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the hepatitis C market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the hepatitis C market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hepatitis C marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the hepatitis C market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the hepatitis C market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the hepatitis C market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of hepatitis C across the seven major markets?

What is the number of prevalent cases (2018-2034) of hepatitis C by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of hepatitis C by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of hepatitis C by type across the seven major markets?

How many patients are diagnosed (2018-2034) with hepatitis C across the seven major markets?

What is the size of the hepatitis C patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of hepatitis C?

What will be the growth rate of patients across the seven major markets?

## Hepatitis C: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for hepatitis C drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatitis C market?

What are the key regulatory events related to the hepatitis C market?

What is the structure of clinical trial landscape by status related to the hepatitis C market?

What is the structure of clinical trial landscape by phase related to the hepatitis C market?

What is the structure of clinical trial landscape by route of administration related to the hepatitis C market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 HEPATITIS C - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 HEPATITIS C - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 HEPATITIS C - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 HEPATITIS C - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 HEPATITIS C - UNMET NEEDS**

## **10 HEPATITIS C - KEY ENDPOINTS OF TREATMENT**

## **11 HEPATITIS C - MARKETED PRODUCTS**

- 11.1 List of Hepatitis C Marketed Drugs Across the Top 7 Markets



- 11.1.1 Olysio (Simeprevir) - Medivir/Janssen R&D Ireland
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Sovaldi (Sofosbuvir) - Gilead Sciences
  - 11.1.2.1 Drug Overview
  - 11.1.2.2 Mechanism of Action
  - 11.1.2.3 Regulatory Status
  - 11.1.2.4 Clinical Trial Results
  - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Vosevi (Sofosbuvir/velpatasvir/voxilaprevir) - Gilead Sciences
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Epclusa (Sofosbuvir/velpatasvir) - Gilead Sciences
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Pegasys (Peginterferon alfa-2a) - Roche
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 HEPATITIS C - PIPELINE DRUGS**

- 12.1 List of Hepatitis C Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 VGX-6150 - GeneOne Life Science
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 TG-2349 - Dongguan HEC TaiGen Biopharmaceuticals
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 SH229 - Nanjing Sanhome Pharmaceutical
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. HEPATITIS C - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. HEPATITIS C – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 HEPATITIS C - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Hepatitis C - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Hepatitis C - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States

- 15.3.1 Hepatitis C - Market Size
  - 15.3.1.1 Market Size (2018-2023)
  - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Hepatitis C - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Hepatitis C - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Hepatitis C - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Hepatitis C - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Hepatitis C - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Hepatitis C - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Hepatitis C - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Hepatitis C - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Hepatitis C - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Hepatitis C - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Hepatitis C - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Hepatitis C - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Hepatitis C - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Hepatitis C - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Hepatitis C - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Hepatitis C - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

### 15.8.3 Hepatitis C - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Hepatitis C - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Hepatitis C - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Hepatitis C - Access and Reimbursement Overview

## **16 HEPATITIS C - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 HEPATITIS C MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 HEPATITIS C MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Hepatitis C Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/HD19452106C3EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD19452106C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

